Advertisement

Journal of Clinical Immunology

, Volume 39, Issue 8, pp 849–851 | Cite as

Interstitial Lung Disease Frequently Precedes CVID Diagnosis

  • Leif G. HanitschEmail author
  • Kirsten Wittke
  • Anna Barbara Stittrich
  • Hans Dieter Volk
  • Carmen Scheibenbogen
Letter to Editor
  • 65 Downloads

To the editor:

Common variable immunodeficiency disorder (CVID) is the most frequent clinically relevant primary immunodeficiency, and pulmonary infections, often leading to the development of bronchiectasis, are a major clinical finding in CVID patients [1]. However, non-infectious manifestations of the lung occur frequently too, with previous studies reporting interstitial lung diseases (ILD) in 10–20% of patients with CVID [1, 2, 3] and a disease onset of non-infectious pulmonary manifestations after 8 years [2]. CVID patients suffering from ILD have a poorer clinical prognosis [4]. Due to its main clinical manifestations, the term “granulomatous lymphocytic interstitial lung disease (GLILD)” was coined; however, clinical and histopathological findings show substantial heterogeneity, and a clear and universal definition is missing.

Other non-infectious manifestations, like immune thrombocytopenia or autoimmune hemolytic anemia, often precede the clinical symptoms and diagnosis of...

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

10875_2019_708_MOESM1_ESM.docx (23 kb)
ESM 1 (DOCX 22 kb)

References

  1. 1.
    Kellner ES, Fuleihan R, Cunningham-Rundles C. USIDNET Consortium, Wechsler JB. Cellular defects in CVID patients with chronic lung disease in the USIDNET registry. J Clin Immunol. 2019;39(6):569–76.CrossRefGoogle Scholar
  2. 2.
    Mannina A, Chung JH, Swigris JJ, Solomon JJ, Huie TJ, Yunt ZX, et al. Clinical predictors of a diagnosis of common variable immunodeficiency-related granulomatous-lymphocytic interstitial lung disease. Ann Am Thorac Soc. 2016 Jul;13(7):1042–9.CrossRefGoogle Scholar
  3. 3.
    Rao N, Mackinnon AC, Routes JM. Granulomatous and lymphocytic interstitial lung disease: a spectrum of pulmonary histopathologic lesions in common variable immunodeficiency – histologic and immunohistochemical analyses of 16 cases. Hum Pathol. 2015;46:1306–14.CrossRefGoogle Scholar
  4. 4.
    Bates CA, Ellison MC, Lynch DA, Cool CD, Brown KK, Routes JM. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol. 2004;114:415–21.CrossRefGoogle Scholar
  5. 5.
    Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun. 2005;25:57–62.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Leif G. Hanitsch
    • 1
    Email author
  • Kirsten Wittke
    • 1
  • Anna Barbara Stittrich
    • 1
  • Hans Dieter Volk
    • 1
    • 2
  • Carmen Scheibenbogen
    • 1
    • 2
  1. 1.Outpatient Clinic for Immunodeficiencies, Institute for Medical ImmunologyCharité-UniversitätsmedizinBerlinGermany
  2. 2.Berlin Institute of Health (BIH), Center for Regenerative Therapies (BCRT)Charité-Universitätsmedizin Berlin and Max Delbrück CenterBerlinGermany

Personalised recommendations